Published in Lancet on April 14, 2007
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol (2008) 1.83
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother (2007) 1.21
A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One (2011) 1.00
Recent progress in antiretrovirals--lessons from resistance. Drug Discov Today (2008) 0.92
Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes. J Virol Methods (2016) 0.75
Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies. Bioorg Med Chem (2010) 0.75
Anti-HIV drug development through computational methods. AAPS J (2014) 0.75
Computational design of a full-length model of HIV-1 integrase: modeling of new inhibitors and comparison of their calculated binding energies with those previously studied. J Mol Model (2013) 0.75
[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]. Med Clin (Barc) (2005) 1.78
Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain). J Acquir Immune Defic Syndr (2008) 1.68
Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagn Microbiol Infect Dis (2008) 1.58
HIV drug and supply stock-outs in Latin America. Lancet Infect Dis (2011) 1.45
Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005. Enferm Infecc Microbiol Clin (2011) 1.43
Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS One (2010) 1.37
Mobility and HIV in Central America and Mexico: a critical review. J Immigr Minor Health (2012) 1.36
Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One (2013) 1.16
Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood (2012) 1.12
Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. J Neurovirol (2005) 1.01
Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. J Int AIDS Soc (2011) 0.97
Inclusion of trans women in pre-exposure prophylaxis trials: a review. AIDS Care (2014) 0.96
Factors associated with healthcare avoidance among transgender women in Argentina. Int J Equity Health (2014) 0.91
Acceptability of HIV Pre-exposure Prophylaxis (PREP) Among People Who Inject Drugs (PWID) in a Canadian Setting. AIDS Behav (2015) 0.89
Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation (2002) 0.88
Behçet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy. Isr Med Assoc J (2006) 0.88
Patient-provider perceptions on engagement in HIV care in Argentina. AIDS Care (2013) 0.84
ICOS, SLAM and PD-1 expression and regulation on T lymphocytes reflect the immune dysregulation in patients with HIV-related illness with pulmonary tuberculosis. J Int AIDS Soc (2012) 0.81
Update on antiretroviral treatment during primary HIV infection. Expert Rev Anti Infect Ther (2014) 0.80
Routine HIV testing among hospitalized patients in Argentina. is it time for a policy change? PLoS One (2013) 0.80
Prevalence of dihydropteroate synthase genotypes before and after the introduction of combined antiretroviral therapy and their influence on the outcome of Pneumocystis pneumonia in HIV-1-infected patients. Diagn Microbiol Infect Dis (2010) 0.79
Dynamics of adrenal steroids are related to variations in Th1 and Treg populations during Mycobacterium tuberculosis infection in HIV positive persons. PLoS One (2012) 0.78
Progress of implementation of the World Health Organization strategy for HIV drug resistance control in Latin America and the Caribbean. Rev Panam Salud Publica (2011) 0.78
A novel educational strategy targeting health care workers in underserved communities in Central America to integrate HIV into primary medical care. PLoS One (2012) 0.78
Examining Adherence Among Challenging Patients in Public and Private HIV Care in Argentina. AIDS Behav (2015) 0.77
[Advances in the diagnosis and treatment of acute human immunodeficiency virus type 1 (HIV-1) infection]. Enferm Infecc Microbiol Clin (2004) 0.76
Boosting HIV treatment options: good news, new challenges. J Infect Dis (2013) 0.76
The coughing patient: TB or not TB; that is the question. J Acquir Immune Defic Syndr (2010) 0.75
[Antiretroviral therapy in patients with primary HIV infection (corrected)]. Med Clin (Barc) (2006) 0.75
Modification of the HIV-specific CD8+ T-cell response in an HIV elite controller after chikungunya virus infection. AIDS (2016) 0.75
Treatment as prevention: are Argentinean HIV care providers willing to adopt earlier antiretroviral therapy? AIDS Care (2014) 0.75